HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Update: 2025-11-20
Description
Featuring an interview with Dr Erika Hamilton, including the following topics:
- General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00 )
- Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11 )
- Mechanisms of resistance to endocrine therapy (10:08 )
- Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26 )
- Other applications for PROTACs (24:24 )
- Emerging data from the Phase III evERA trial (27:38 )
- Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51 )
Comments
In Channel























